Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Public ClinicalTrials.gov record NCT03229200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Study identification
- NCT ID
- NCT03229200
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Pharmacyclics Switzerland GmbH
- Industry
- Enrollment
- 297 participants
Conditions and interventions
Conditions
Interventions
- Ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2017
- Primary completion
- May 9, 2027
- Completion
- May 9, 2027
- Last update posted
- Oct 29, 2025
2017 – 2027
United States locations
- U.S. sites
- 34
- U.S. states
- 17
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center | Burbank | California | 91505 | — |
| City Of Hope National Medical Center | Duarte | California | 91010 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92093-0698 | — |
| University of California Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Stanford University | Stanford | California | 94305 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Norton Medical Plaza II, 3991 Dutchmans Lane | Louisville | Kentucky | 40207 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| TRIO - Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169-3321 | — |
| John Theurer Cancer Center, Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Northwell Health | New Hyde Park | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065-6007 | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | 10065 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Southeastern Medical Oncology Center | Goldsboro | North Carolina | 27534-9479 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| M.D. Anderson Cancer Centre | Houston | Texas | 77030 | — |
| US Oncology Research, LLC | The Woodlands | Texas | 77380 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05405 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Northwest Cancer Specialists, Compass Oncology | Vancouver | Washington | 09868 | — |
| Wenatchee Valley Hospital and Clinics | Wenatchee | Washington | 98801 | — |
| Yakima Valley Memorial Hospital | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03229200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03229200 live on ClinicalTrials.gov.